期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

初次手术辅以化疗后血清HE4水平对卵巢癌患者复发时间的影响

下载PDF
导出
摘要 目的探讨卵巢癌患者术后化疗后血清HE4降至正常范围的HE4水平对复发时间的影响。方法选择100例卵巢浆液性乳头状囊腺癌Ⅲ期或Ⅳ期患者,均行初次肿瘤细胞减灭术,术后辅以铂类药物为主的联合化疗后HE4均降至正常水平,根据术后化疗后的HE4值将患者分为4组。结果 4组患者预后比较,A、B、C、D组复发时间分别为32、24、18、3个月,A、B及C组分别与D组比较,差异均有统计学意义(P<0.05);而A、B、C 3组间比较,差异均无统计学意义(P>0.05)。结论卵巢癌患者肿瘤细胞减灭术后接受以铂类为主的联合化疗后血清HE4水平正常的卵巢癌患者的血清HE4水平对其复发时间有一定影响。
作者 李俊青 孙立新
机构地区 山西医科大学 山西医科大学附属山西省肿瘤医院
出处 《中国医药指南》 2014年第10期128-129,共2页 Guide of China Medicine
关键词 卵巢浆液性乳头状囊腺癌 肿瘤细胞减灭术 铂类药物为主的联合化疗 HE4水平 复发时间
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献8

  • 1Earle CC,Schrag D,Neville BA,et al.Efkct of surgeon specialty on processesof careand outcomes for ovarian eancer patients[J]. J Natl Cancer Inst,2006,98(3):172-180.
  • 2MooreRG,BastRC Jr.How do you distinguish a malignantp elvicmass from a benign pelvic mass?Imang,biomarkers,ornone of the above[J].J Clin Oncol,2007,25(27):4159-4161.
  • 3Coonewardene TI,Hau MR.Management 0 asymptomatic patientson followup for ovarian callcer with risingCA-125 concentmtions[J].Iancet Oncol,2007,8:813-821.
  • 4马二玲,刘越飞,刘晓旭,等.HE4作为卵巢癌肿瘤标志物的研究进展[J].河北医学,2012,34(1):112-115.
  • 5林巧稚.妇科肿瘤学[M].3版.北京:人民卫生出版社,2000:461.
  • 6Therasse P, Arbuck SG.New guidelines to evaluate ther response treatment in solidi umors.European Organization for Research anti Treatment of Cancer,National Cancer Institute of the Unite(IStates,National Cancer Institute of Canada[J].J Natl Cmleer Insl,2000,92:205-216.
  • 7Rustin GJ,Nelstrop AE,Tuxen MK,et al.Defining progression of ovarian earcinomad Uring follow-upart-onlin toCA 125:a NorthThames Ovary.Group Study[J].Ann Onco1,1996,7:361-364.
  • 8牟田,李小平,王建六,王世军,王悦,孙秀丽,崔恒,魏丽惠.初次手术辅以化疗后血清CA125水平变化对卵巢上皮性癌患者行间歇性肿瘤细胞减灭术及预后的意义[J].中华妇产科杂志,2012,47(8):566-570. 被引量：9

二级参考文献11

  • 1Ozols RF. Treatment goals in ovarian cancer. Int J Gynecol Cancer,2005,15 Suppl 1:3-11.
  • 2Herrin VE, Thigpen T. Recent development in the treatment of recurrent ovarian carcinoma. Adv 0ncol,2000,16:21-29.
  • 3Onda T, Kobayashi H, Nakanishi T, et al. Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage II1/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Ontology Group Study JCOG0206. Gynecol Oncol,2009, 113:57-62.
  • 4Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst,2000,92:205-216.
  • 5Rustin GJ, Nelstrop AE, Tuxen MK, et al. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol, 1996,7:361-364.
  • 6Morice P, Brehier-Ollive D, Rey A, et al. Results of interval debulking surgery in advanced stage ovarian cancer: an exposed- non-exposed study. Ann Oncol,2003,14:74-77.
  • 7Guhekin M, Diribas K, Buru E, et al. Interval debulking in epithelial ovarian carcinomas:the past, present and the future. Eur J Gynaecol 0ncol,2008,29:242-245.
  • 8Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol, 2002,20 : 1248-1259.
  • 9Winter WE 3rd, Maxwell GL, Tian C, et al. Tumor residual alter surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer:a Gynecologic Oncology Group Study. J Clin Oncol, 2008,26 : 83-89.
  • 10van der Burg ME, Vergote I, Gynecological Cancer Group of the EORTC. The role of interval debulking surgery in ovarian cancer. Curr Oncol Rep,2003,5:473-481.
中国医药指南
2014年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部